Search

Cancer is one of the fatal diseases that cause many deaths around the world. Lung cancer has the highest incidence and mortality rates among cancer-related death worldwide. Lung cancer is a common malignant tumor that poses a severe threat to human life due to its high prevalence and mortality. There are no early screening biomarkers for lung cancer. Patients with lung cancer are often diagnosed in the middle and advanced stages of the disease that show unfavorable clinical outcomes. Chemotherapy, radiation therapy, and surgical removal are commonly used to cure lung cancer. Chemotherapy is among the most common techniques for treating lung cancer. Due to the incredibly low delivery potency and non-specificity of anti-cancer medications, systematic chemotherapy is limited in clinical effectiveness and has significant toxic side effects. Despite continued medical advances, lung cancer nevertheless needs successful treatment. Nanotechnology has recently emerged as a potential approach to lung cancer management and care. Present therapies have been transformed by nanotechnology, which focuses on reducing toxicity and enhancing the bioavailability of anticancer medications in tumor cells. However, nanotechnology would have to tackle many challenges to gain traction in lung cancer treatment. This article reviews the latest literature on the use of nano-drug delivery mechanisms in lung cancer treatment. This research aims to propose new ideas for developing nanocarriers for lung cancer drug delivery. [ABSTRACT FROM AUTHOR]

Purpose: The main objective of the research was to formulate an effervescent floating matrix tablet (EFMT) of a potential anticancer drug neratinib employed in breast cancer therapy. The drug shows poor aqueous solubility at higher pH leading to reduce therapeutic efficacy, thereby resulting in poor bioavailability. Hence, an EFMT is designed to extend the gastric residence time (GRT) of drugs, which can remain several hours in the gastric region and enhance bioavailability. Further 23 factorial design employed. Methods: The EFMT of neratinib are prepared by direct compression using hydroxyl propyl methylcellulose, Carbopol 940, microcrystalline cellulose, sodium bicarbonate, talc, and lactose. Polymer concentrations were selected as independent variables, whereas hardness, percentage swelling, floating, and percentage drug release were the dependent variables. Pre- and post-compression measurements, swelling studies, in vitro buoyancy, FTIR, scanning electron microscopy (SEM), in vitro release, kinetic, and mechanism of drug release studies have been characterized for preparing floating matrix tablets Results: The results showed that pre-and post-compression parameters are within the limit of USP. The buoyancy lag time and total buoyancy time are less than 2 min and > 12 h, respectively, with good swelling characteristics. Fourier transform infrared (FTIR) spectrum showed that no interaction was found between drug and polymers. The optimized formulation (F9) showed 100% drug release at 8 h, which shows a Fickian diffusion. Conclusion: The developed novel neratinib floating matrix tablet could enhance the solubility and residence time of neratinib at upper GIT because of the combined effect of the polymers. [ABSTRACT FROM AUTHOR]